Profound Medical and Telix sign co-education deal on prostate care

Go back to Profound Medical and Telix sign co-education deal on prostate care

Profound Medical and Telix Pharmaceuticals Enter Co-Education Agreement to Advance PSMA-Informed Prostate Care

October 9, 2026 7:45 AM EDT

Collaboration will educate physicians and prostate cancer centers on the complementary roles of Telixs PSMA-PET molecular imaging technologies and Profounds MRI-guided TULSA-PRO®

Agreement provides Profound with increased access to urologists via a strong strategic partner and creates a framework to further advance clinical evidence-based patient selection and optimization of patient treatment plans

TORONTO, Oct. 09, 2026 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (Profound or... More